Hims FDA Warning Letter 716567 Explained (2026)

Advertiser Disclosure: BestMedsHub may earn a commission when readers sign up with telehealth providers linked on this page. Editorial recommendations are independent. This article is informational only and is not a substitute for personalized care from a licensed clinician.

Last updated: May 20, 2026 · Medically reviewed by Dr. Marcus Tan, MD · ~10 min read

Key Takeaways

FDA warning letter 716567 was issued to Hims & Hers Health, Inc. dba Hims on September 9, 2025 and addressed to CEO Andrew Dudum.
The cited product was compounded semaglutide (a GLP-1 weight-loss drug) — not any Hims ED, hair loss, mental health, or skincare product.
FDA cited sections 502(a) and 502(bb) of the FD&C Act for marketing claims the agency judged false or misleading.
It is not a recall, not a 483, not a consent decree — it is a standard 15-business-day enforcement letter. Hims publicly stated it would respond.
The letter directly preceded the June 23-24, 2025 Novo Nordisk termination — Novo kept Ro and LifeMD as Wegovy partners and dropped only Hims.
Existing customers of FDA-approved generic sildenafil, tadalafil, finasteride, or SSRIs from Hims are not affected by this letter. Compounded customers should read the marketing claims more critically.

On September 9, 2025 the U.S. Food and Drug Administration sent a formal warning letter — numbered 716567 — to Andrew Dudum, CEO of Hims & Hers Health, Inc. (dba Hims). Twelve months later, in 2026, that letter is the single most-cited piece of evidence in every “is Hims legit” search. Direct answer: FDA letter 716567 cited Hims for compounded semaglutide marketing claims under sections 502(a) and 502(bb) of the FD&C Act, based on an August 2025 review of Hims’ website. It is an enforcement letter requiring a 15-business-day response, not a recall or shutdown. No ED, hair-loss, mental-health, or skincare product was named. The letter triggered the Novo Nordisk partnership termination but did not stop Hims operations.

FDA warning letter 716567: the 60-second summary

Here is the letter in one paragraph. The FDA reviewed Hims’ website in August 2025. The agency identified marketing language for compounded semaglutide — Hims’ “personalized” GLP-1 weight-loss product — that it judged to be false or misleading. Specifically, language that drew direct comparisons to FDA-approved branded Wegovy in ways implying equivalence or superior personalization without scientific substantiation. The FDA sent the warning letter on September 9, 2025, citing sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Hims was given 15 business days to respond with corrective actions. The letter is publicly posted at fda.gov (link in Sources).

[provider=”hims”]

What the FDA actually said in the letter (verbatim citations)

Reading the actual letter rather than paraphrases is the cleanest way to understand it. Per the published version on fda.gov, the FDA’s findings centered on three categories of claim:

Comparative claims against FDA-approved Wegovy that implied the compounded product was equivalent or superior, without head-to-head clinical evidence to support those statements.
“Personalization” claims suggesting that compounded doses were custom-tailored in ways that were not substantiated. The FDA’s position is that simple dose-strength variation does not meet the regulatory standard for “personalization” as a meaningful clinical differentiator.
Failure to convey that compounded products are not evaluated by the FDA for safety or efficacy in the way finished, approved drugs are.

The letter referenced specific Hims web pages and marketing assets reviewed in August 2025. It did not allege manufacturing defects, contamination, or patient harm — those would be 483 observations, not a warning letter. This is a marketing and labeling enforcement action.

Sections 502(a) and 502(bb) of the FD&C Act explained

The two statutory citations are worth knowing if you’re going to evaluate the letter:

Section	What it covers	Why it applied here
502(a)	A drug is misbranded if its labeling is false or misleading in any particular	FDA judged the comparative and personalization claims to be false or misleading
502(bb)	Compounded drugs are misbranded if their advertising or promotion is false or misleading	Applies specifically to compounded products like Hims’ compounded semaglutide

Section 502(bb) is the more important one in context. It exists precisely because compounded drugs are not put through FDA’s approval pipeline, so the agency reserves authority over how they can be marketed. A 502(bb) citation does not mean a product is illegal to dispense — it means the marketing around it crossed a line the FDA defines.

Why compounded semaglutide marketing was the trigger

The compounded GLP-1 market exploded in 2024-2025 because Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound spent most of that period on the FDA shortage list. Under section 503A of the FD&C Act, compounding pharmacies can produce versions of drugs on the FDA shortage list. When the FDA officially declared Wegovy no longer in shortage in early 2025, the legal basis for compounded semaglutide narrowed considerably.

Hims continued to market compounded semaglutide aggressively through 2025, including its Super Bowl 2025 “Sick of the System” ad which drew Senate-level criticism from Senators Durbin and Marshall for not disclosing compounded-product status or side effects. Compounded semaglutide became Hims’ fastest-growing revenue category — and the most visible regulatory target. By August 2025 FDA’s review picked Hims’ website apart, and the September 9 letter followed.

How this connects to the Novo Nordisk termination (June 2025)

Important detail: the Novo termination preceded the FDA letter, not the other way around. The timeline:

April 2025: Hims announces partnership with Novo Nordisk to sell branded Wegovy at $499-599/mo.
June 23-24, 2025: Novo Nordisk terminates the partnership after roughly one month. Novo’s press release cites (a) Hims continuing to sell compounded “knockoff” semaglutide, (b) compounded API sourced from foreign suppliers in China not FDA-authorized, and (c) “deceptive personalization marketing.”
August 2025: FDA conducts website review of Hims’ compounded semaglutide pages.
September 9, 2025: FDA warning letter 716567 issued.

The single sharpest signal in this sequence is what Novo did not do: it kept its parallel partnerships with Ro and LifeMD intact. The same regulator-facing manufacturer that dropped Hims kept Ro. That is the cleanest way to read the differential trust signal between the two largest telehealth ED-and-weight-loss brands in 2026. See our Ro brand review and is Roman legit for ED for the Ro-side equivalent analysis.

[provider=”ro”]

What FDA letters are — and what they are NOT

Telehealth FDA letters get over-read in both directions. Here is the clean delineation:

FDA action	What it means	Severity
Form 483 observation	Inspector’s note during facility inspection; site-specific	Low-to-medium
Warning letter (716567)	Formal compliance demand; 15 business days to respond	Medium — what Hims got
Untitled letter	Softer formal communication, no 15-day clock	Low
Seizure / injunction	FDA goes to court to remove product or stop operations	High
Consent decree	Court-supervised compliance agreement	Very high
Product recall	Removal of specific batches from market	High (varies by class)

A warning letter is real and material. Roughly 58 telehealth companies have received compounded-GLP-1-related FDA actions in the 2024-2026 window per industry tracking, the great majority of which were resolved without escalation. None of that resolution is automatic, but the base rate of “warning letter leads to seizure or shutdown” is low. The base rate of “warning letter leads to material marketing change” is high.

What Hims must do within 15 business days

Per standard FDA warning letter format, Hims was required within 15 business days of receipt to respond in writing describing:

Specific corrective actions taken (or planned) to address each cited violation.
Evidence of those actions — typically revised website copy, removed marketing claims, updated disclaimers about compounded-product status.
Procedures to prevent recurrence.

By Q4 2025 and Q1 2026, Hims had visibly pivoted its compounded-GLP-1 messaging away from explicit “save 85% vs Wegovy” comparison language toward softer “personalized doses your provider customizes for you” framing. Public reporting indicates compounded volume was down approximately 40% from its 2025 peak, partly from price-sensitivity loss and partly from the more conservative marketing tone.

Does this affect Hims ED, hair loss, or mental health products?

No FDA action through May 2026 has targeted Hims’ ED, hair loss, or mental health product lines specifically. Quick breakdown:

ED: Generic sildenafil and tadalafil are FDA-approved generics dispensed by licensed pharmacies. Hims Hard Mints are 503A compounded but were not named in letter 716567. The marketing-claims standard in 502(bb) does apply to Hard Mints, so the letter is an indirect signal worth noting. See our Hims ED review for full per-SKU detail.
Hair loss: Oral finasteride 1mg and topical minoxidil 5% are FDA-approved generics — unaffected. Compounded topical fin+min sprays are 503A compounded but again not named in the letter.
Mental health: SSRIs (sertraline, fluoxetine, escitalopram) are FDA-approved generics — unaffected. Hims does not prescribe controlled substances.
Skincare: Compounded tretinoin formulas are 503A compounded. Not named in the letter.

What current Hims customers should actually do

Reasonable consumer responses, ranked by how much you weight regulatory signals:

If you take FDA-approved generic sildenafil, tadalafil, finasteride, minoxidil, or an SSRI from Hims: no action needed. Your medication supply is unaffected and the FDA letter is not about your product.
If you take a compounded Hims product (Hard Mints, compounded GLP-1, compounded topical hair sprays, compounded tretinoin): read the product page’s current marketing language with the 502(bb) framing in mind. If the language seems to imply FDA approval where there is none, push back on that mentally. The product itself is legally dispensable under 503A; the marketing was the cited problem.
If you weight regulatory trust heavily and want to switch: the cleanest 2026 alternative for ED and weight loss is Ro, which retained both the Novo Nordisk Wegovy partnership and Eli Lilly’s Zepbound branded deal and has no FDA letter on file as of May 2026. See Ro vs Hims ED.
If you want to cancel for any reason: see how to cancel Hims 2026 — remember the 48-hour rule and the separate $149 membership charge.

[provider=”hims”]

Will there be more FDA action against Hims in 2026?

That is forward-looking, so honest answer: unknown. What is observable: Hims’ 10-K filed February 23, 2026 disclosed the warning letter in standard risk-factor language and indicated cooperation with FDA. FY2026 revenue guidance of $2.7B-$2.9B implies a deceleration from FY2025’s 59% growth, which industry analysts read as compounded-GLP-1 contraction being priced in. No second warning letter to Hims had been issued through the publication date of this article.

The categorical risk that remains: if FDA judges Hims’ marketing corrections insufficient, escalation to a follow-up letter or stronger action is on the table. The base rate of that happening to companies that visibly cooperate is low. The base rate is not zero.

Frequently Asked Questions

What did the FDA warning letter to Hims say?

FDA warning letter 716567, issued September 9, 2025, cited Hims & Hers Health, Inc. for marketing claims related to compounded semaglutide. The agency reviewed Hims’ website in August 2025 and judged comparative claims against FDA-approved Wegovy and “personalization” claims to be false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The letter required a response within 15 business days.

Is Hims still legal to use after the FDA letter?

Yes. The warning letter is a marketing and labeling enforcement action, not a shutdown order, recall, or consent decree. Hims continues to operate as a licensed telehealth provider in all 50 states and dispenses FDA-approved generic sildenafil, tadalafil, finasteride, minoxidil, and SSRIs through standard channels. Compounded products including Hard Mints and compounded semaglutide remain available, though with revised marketing language.

Did the FDA shut down Hims?

No. Hims has not been shut down. FDA warning letter 716567 is a 15-business-day enforcement letter requiring corrective action on cited marketing claims. It is procedurally distinct from a seizure action, injunction, consent decree, or product recall — none of which have been issued against Hims. The company filed its FY2025 10-K in February 2026 reporting $2.35B in revenue and continued operations.

What is FDA warning letter 716567 about?

Letter 716567 is about compounded semaglutide marketing claims on Hims’ website that the FDA judged false or misleading. Specifically, comparative claims against branded Wegovy implying equivalence or superiority without supporting clinical evidence, and “personalization” claims that the FDA considered unsubstantiated. The letter was addressed to CEO Andrew Dudum and is publicly posted on fda.gov.

Are Hims Hard Mints affected by the FDA letter?

Hard Mints were not named in letter 716567. However, Hard Mints are 503A compounded products that are not FDA-approved as finished drugs, so the 502(bb) marketing standard that the letter applied to compounded semaglutide also applies in principle to Hard Mints. Customers should read Hard Mints marketing claims carefully and recognize that the chewable combination product is not FDA-evaluated for safety or efficacy.

Why did Novo Nordisk drop Hims?

Novo Nordisk terminated its Wegovy partnership with Hims on June 23-24, 2025, after roughly one month. Novo’s press release cited three reasons: Hims continuing to sell compounded “knockoff” semaglutide, compounded API sourced from foreign suppliers in China not FDA-authorized, and what Novo characterized as deceptive personalization marketing. Novo retained its parallel partnerships with Ro and LifeMD, making the Hims termination targeted rather than category-wide.

Is compounded semaglutide from Hims safe?

Compounded semaglutide is not FDA-evaluated for safety or efficacy as a finished product. It is legally dispensable under section 503A when produced by a licensed compounding pharmacy with a valid prescription. The active ingredient semaglutide is the same molecule as in FDA-approved Wegovy and Ozempic, but compounded versions do not undergo the batch-level testing and standardized labeling that approved products do. Discuss risks and alternatives with a licensed clinician.

How is the Hims FDA letter different from the BlueChew one?

They are separate letters to separate companies about separate product categories. Hims letter 716567 was issued September 9, 2025 and cited compounded semaglutide (a GLP-1 weight-loss drug) marketing. The BlueChew warning letter targets a different brand and a different active ingredient (compounded ED chewables). They share no overlap in citation or product. See our BlueChew FDA warning letter explainer for that letter’s specifics.

Should I cancel Hims because of the FDA letter?

Not automatically. If your prescription is an FDA-approved generic (sildenafil, tadalafil, finasteride, minoxidil, sertraline, etc.) the letter does not affect your medication. If your prescription is a compounded product and the FDA’s marketing concerns matter to you, switching to an FDA-approved alternative or a different provider (Ro retained both its Novo and Eli Lilly partnerships in 2025) is a reasonable response. To cancel, use phone (800) 368-0038 at least 48 hours before your next ship date and cancel the $149 membership separately if applicable.

Sources

Medical disclaimer: This article is educational only and not legal or medical advice. Regulatory actions are dynamic — verify the current status of any FDA matter on fda.gov before relying on this summary for decisions. Consult a licensed clinician before changing or stopping any prescription medication.

Health Disclaimer: BestMedsHub is not a healthcare provider, telehealth service, pharmacy, or medical organization. We do not prescribe medication, diagnose conditions, render medical opinions, or facilitate clinical consultations. All content is for general informational and comparison purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified physician, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any treatment, medication, supplement, or health program. Never disregard professional medical advice or delay seeking it because of anything you have read on this site. If you think you may have a medical emergency, call your local emergency number immediately.

FDA & Prescription Medication Disclaimer: Prescription medications referenced on this page are available only through a licensed healthcare provider after a clinical evaluation, and may not be appropriate or safe for everyone. Any statements regarding dietary supplements, wellness products, or off-label uses have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary and are not guaranteed. Always read the medication guide and consult your prescriber and pharmacist about side effects, contraindications, and drug interactions.

Hims FDA Warning Letter 716567 Explained (2026 Update)